



Progress in the Systemic Therapy of Urological Oncology

Guest Editor:

Dr. Anna Patrikidou

Genito-Urinary Oncology Team,
Department of Cancer Medicine
and Drug Development and
Innovation Department, Gustave
Roussy, Université Paris-Saclay,
114 Rue Edouard Vaillant, 94800
Villejuif, France

Deadline for manuscript
submissions:

closed (30 May 2025)

Message from the Guest Editor

Progress in the systemic therapy of urological oncology has been extraordinary. New treatments, such as immunotherapies, hormonal and targeted therapies, antibody-drug conjugates and radioligand therapies, have improved survival rates and quality of life for patients with various urological cancers. Additionally, precision medicine tools, utilising various platforms of molecular testing, have allowed for more personalised treatment plans. We are now entering an era of carefully crafting de-escalation and intensification approaches for metastatic disease, as well as intelligent early relapse detection and adjuvant therapy strategies. Our next generation clinical trials are biomarker-guided, such as minimal residual disease detection surrogates, that range from simple proteins (PSA in prostate cancer or PD-L1 expression in renal cancer), to microRNAs (miRNA-371 in testicular cancer) or ctDNA detection (urothelial cancer), or even radiomics (PSMA and other metabolic imaging in prostate cancer). This Special Issue invites papers on systemic therapies (e.g. chemotherapy, hormone therapy, immunotherapy, targeted therapy, radioligand therapies, novel therapeutics) in urological cancers.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)